Abstract Intravenous (IV) catheters provide an essential means for rapid, controlled drug delivery directly into the bloodstream, yet they also pose a serious risk of catheter-related bloodstream infections (CRBSIs). CRBSIs represent a significant clinical challenge, leading to patient complications, increased healthcare costs, and longer hospital stays. With a substantial market size of approximately USD 8.6…